1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

Sandoz, Viatris Look To Be In Commercial Vanguard; Supply Core, CDMOs Vital

 
• By Dean Rudge

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Generics producers are keen for a piece of the GLP-1 pie

With the addition of weight loss and obesity indications and more patient-friendly dosing regimens beginning at the start of the current decade, glucagon-like-peptide-1 (GLP-1) receptor agonists have exploded into a multi-billion-dollar, cultural phenomenon, comparable in the prescription pharma space to the arrival of Viagra (sildenafil) in the late 1990s or Botox (onabotulinumtoxinA) before it.

The global market for such products has been tipped to reach $71bn by 2032, or even as high as $100bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

 
• By Dean Rudge

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

More from Generics Bulletin Perspectives

Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

 
• By Dean Rudge

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Biosimilar Year In Review: Regulatory Achievements And Future Aspirations

 
• By Urtė Fultinavičiūtė

This year, regulators questioned the US interchangeability designation and the need for comparative efficacy trials, while finding ways to promote biosimilar development and accessibility. Will this momentum continue in 2025? Generics Bulletin spoke to experts from across the industry to hear their views.

The Generics Bulletin Podcast: Highlights Of 2024

 
• By Dave Wallace

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.